Cyteir Therapeutics
2 known investors
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.